Edition:
United States

Soleno Therapeutics Inc (SLNO.OQ)

SLNO.OQ on NASDAQ Stock Exchange Capital Market

1.69USD
23 Feb 2018
Change (% chg)

$-0.04 (-2.31%)
Prev Close
$1.73
Open
$1.70
Day's High
$1.70
Day's Low
$1.69
Volume
1,329
Avg. Vol
24,070
52-wk High
$4.10
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome
Tuesday, 20 Feb 2018 08:00am EST 

Feb 20 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS ANNOUNCES SUCCESSFUL END-OF-PHASE II MEETING WITH FDA FOR DCCR IN PRADER-WILLI SYNDROME.SOLENO THERAPEUTICS INC - ‍MINUTES OF MEETING CONFIRMED FDA, CO ALIGNED ON ALL KEY ASPECTS OF CO'S PLANNED PHASE III CLINICAL TRIAL FOR DCCR.  Full Article

Jack W. Schuler Living Trust Reports 13.4 Pct Stake In Soleno Therapeutics As Of December 15
Friday, 12 Jan 2018 06:18am EST 

Jan 12 (Reuters) - Soleno Therapeutics Inc ::JACK W. SCHULER LIVING TRUST REPORTS 13.4 PERCENT STAKE IN SOLENO THERAPEUTICS INC AS OF DECEMBER 15 - SEC FILING.  Full Article

Birchview Capital LP Reports A 6.17 Pct Passive Stake In Soleno Therapeutics
Tuesday, 26 Dec 2017 05:26pm EST 

Dec 26 (Reuters) - Soleno Therapeutics Inc ::BIRCHVIEW CAPITAL LP REPORTS A 6.17 PCT PASSIVE STAKE IN SOLENO THERAPEUTICS AS OF DEC 15 - SEC FILING.  Full Article

Soleno Therapeutics Announces $15 Million Private Placement
Tuesday, 12 Dec 2017 08:30am EST 

Dec 12 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS ANNOUNCES $15 MILLION PRIVATE PLACEMENT.SOLENO THERAPEUTICS INC - SOLENO TO SELL 8.1 MILLION OF ITS COMMON SHARES AT $1.8425/SHARE.SOLENO THERAPEUTICS - TO USE PROCEEDS CONDUCT PLANNED PHASE III PROGRAM OF DIAZOXIDE CHOLINE CONTROLLED-RELEASE IN PRADER-WILLI SYNDROME.  Full Article

Soleno Therapeutics Announces Joint Venture Agreement For Commercialization Of Cosense Monitoring Technology
Friday, 8 Dec 2017 08:00am EST 

Dec 8 (Reuters) - Soleno Therapeutics Inc ::SOLENO THERAPEUTICS ANNOUNCES JOINT VENTURE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF COSENSE MONITORING TECHNOLOGY.SOLENO THERAPEUTICS INC - UNDER TERMS OF JV AGREEMENT, OAHL WILL INVEST UP TO $2.2 MILLION IN TRANCHES TO PURCHASE SHARES OF OUR CAPNIA SUBSIDIARY.SOLENO THERAPEUTICS INC - CAPNIA WILL NO LONGER BE A WHOLLY-OWNED SUBSIDIARY OF SOLENO.SOLENO THERAPEUTICS INC - UNDER TERMS OF JV AGREEMENT, GOING FORWARD, OAHL WILL BE RESPONSIBLE FOR FUNDING OPERATIONS OF CAPNIA.  Full Article

Soleno Therapeutics posts Q3 loss $0.24/shr from continuing operations
Tuesday, 14 Nov 2017 08:00am EST 

Nov 14 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.24 from continuing operations.Q3 loss per share $0.35.  Full Article

Soleno Therapeutics announces 1-for-5 reverse stock split
Thursday, 5 Oct 2017 01:00pm EDT 

Oct 5 (Reuters) - Soleno Therapeutics Inc ::Soleno Therapeutics announces 1-for-5 reverse stock split.Soleno Therapeutics - reverse stock split of all of co's outstanding common shares at an exchange ratio of 1-for-5 will take effect on October 6, 2017.  Full Article

Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome
Friday, 15 Sep 2017 08:00am EDT 

Sept 15 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome.Soleno Therapeutics Inc - phase iii study expected to begin by end of 2017.  Full Article

Soleno Therapeutics CFO David O’Toole to transition from Soleno in mid-Sept ‍​
Tuesday, 5 Sep 2017 05:08pm EDT 

Sept 6 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics Inc says David O’Toole, company’s chief financial officer, will transition from Soleno in mid-September - SEC filing ‍​.Says Jonathan R. Wolter appointed interim CFO.  Full Article

Soleno Therapeutics Q2 loss per share $0.07
Friday, 11 Aug 2017 04:05pm EDT 

Aug 11 (Reuters) - Soleno Therapeutics Inc :Soleno Therapeutics provides corporate update and reports second quarter 2017 financial results.Q2 loss per share $0.06 from continuing operations.Q2 loss per share $0.07.Soleno Therapeutics Inc - ‍preparing to begin phase III program by end of year​.  Full Article

BRIEF-Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome

* SOLENO THERAPEUTICS ANNOUNCES SUCCESSFUL END-OF-PHASE II MEETING WITH FDA FOR DCCR IN PRADER-WILLI SYNDROME